| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ze-Hao Zheng, Rui Xiao, Na Liu, Ben-Yi He, Wei Yu, Zhong-Shi Wu, Min-Shan Chen, Jie Mei, Dan-Dan Hu and Rong-Ping Guo |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the National Science and Technology Major Project of China |
2024ZD0520402 |
| Science and Technology Planning Project of Guangzhou |
2023A03J0601 |
|
| Corresponding Author |
Rong-Ping Guo, Department of Hepatobiliary Oncology,, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou, Guangdong, 510060, Peoples Republic of China., Guangzhou 510060, Guangdong Province, China. guorp@sysucc.org.cn |
| Key Words |
Hepatocellular carcinoma; Bevacizumab; Checkpoint inhibitors; Hepatic arterial infusion chemotherapy; C reactive protein; Overall survival |
| Core Tip |
This study validated the prognostic value of the CRAPT-M model in patients with hepatocellular carcinoma receiving locoregional-bevacizumab-immunotherapy. The model effectively stratified overall survival and progression-free survival not only in the locoregional plus atezolizumab plus bevacizumab group but also in the locoregional plus sintilimab plus bevacizumab group. In addition, we developed a Simple-CRAPT-M model based on the number of risk factors, which may provide a more convenient tool for rapid risk stratification in clinical practice. |
| Publish Date |
2026-06-30 13:35 |
| Citation |
Zheng ZH, Xiao R, Liu N, He BY, Yu W, Wu ZS, Chen MS, Mei J, Hu DD, Guo RP. CRAPT-M: An effective prognostic predictor for hepatocellular carcinoma patients treated with locoregional-bevacizumab-immunotherapy. World J Gastroenterol 2026; 32(25): 119588
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i25/119588.htm |
| DOI |
https://doi.org/10.3748/wjg.119588 |
